A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226). (December 2016) - Hao, D.; Juergens, R.; Laurie, S.; Mates, M.; Tehfe, M.; Bradbury, P.; Kollmannsberger, C.; Ellis, P.; Hilton, J.; Brown-Walker, P.; Seymour, L.